Literature DB >> 12890804

Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens.

H-P Horny1, K Lange, K Sotlar, P Valent.   

Abstract

AIMS: To clarify the nature (reactive or neoplastic) of lesional, perifocally aggregated lymphocytes in bone marrow infiltrates of systemic mastocytosis (SM), the histopathology of which can resemble malignant lymphoma with focal bone marrow involvement, particularly low grade malignant B cell lymphoma of lymphoplasmacytic immunocytoma subtype, which frequently exhibits increased mast cell (MC) numbers.
METHODS: Thirteen cases of SM and three of lymphoplasmacytic immunocytoma with predominant focal bone marrow infiltration were investigated. Immunostaining of formalin fixed, paraffin wax embedded bone marrow specimens was performed using antibodies against CD2, CD5, CD20, CD23, and CD25; kappa and lambda immunoglobulin light chains; and MC markers chymase, tryptase, and CD117 (KIT). Monoclonal rearrangements of IgH and TCRgamma were studied using seminested polymerase chain reaction (PCR). c-kit point mutation Asp816-Val was detected by PNA mediated PCR clamping and hybridisation probes.
RESULTS: The lymphocytic clusters in SM contained nearly equal numbers of mature T and B cells, the latter with no coexpression of aberrant antigens, such as CD5 or CD23. Most MCs in SM cases constantly coexpressed tryptase, CD25, and CD117. No monoclonal rearrangements were seen for IgH or TCRgamma. In contrast, B cells from immunocytomas showed light chain restriction and monoclonal rearrangement for IgH, confirming their neoplastic nature. c-kit point mutation Asp816-Val was found in ten of 13 SM cases, but in none of the three immunocytomas.
CONCLUSIONS: Focal accumulations of lymphocytes in the bone marrow of SM are reactive in nature and could be termed lymphocytosis. A diagnosis of SM-AHNMD/immunocytoma should not be made.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890804      PMCID: PMC1770043          DOI: 10.1136/jcp.56.8.575

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.

Authors:  C Akin; A S Kirshenbaum; T Semere; A S Worobec; L M Scott; D D Metcalfe
Journal:  Exp Hematol       Date:  2000-02       Impact factor: 3.084

2.  Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies.

Authors:  W V Li; S B Kapadia; E Sonmez-Alpan; S H Swerdlow
Journal:  Mod Pathol       Date:  1996-10       Impact factor: 7.842

3.  Bone marrow findings in systemic mastocytosis.

Authors:  H P Horny; M R Parwaresch; K Lennert
Journal:  Hum Pathol       Date:  1985-08       Impact factor: 3.466

Review 4.  Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Authors:  P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

Review 5.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

Authors:  H P Horny; P Valent
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

6.  Diagnostic value of immunostaining for tryptase in patients with mastocytosis.

Authors:  H P Horny; C Sillaber; D Menke; E Kaiserling; M Wehrmann; B Stehberger; A Chott; K Lechner; K Lennert; P Valent
Journal:  Am J Surg Pathol       Date:  1998-09       Impact factor: 6.394

7.  Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan.

Authors:  T Hongyo; T Li; M Syaifudin; R Baskar; H Ikeda; Y Kanakura; K Aozasa; T Nomura
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

8.  An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells.

Authors:  Cem Akin; Elaine S Jaffe; Mark Raffeld; Arnold S Kirshenbaum; Trisha Daley; Pierre Noel; Dean D Metcalfe
Journal:  Am J Clin Pathol       Date:  2002-08       Impact factor: 2.493

9.  Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders.

Authors:  M Prokocimer; A Polliack
Journal:  Am J Clin Pathol       Date:  1981-01       Impact factor: 2.493

10.  Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: a histological and immunohistological study.

Authors:  H P Horny; E Kaiserling
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

View more
  5 in total

1.  Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.

Authors:  Shouying Du; Hooman H Rashidi; Dzung T Le; Thomas J Kipps; H Elizabeth Broome; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

2.  An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).

Authors:  H-P Horny; K Sotlar; F Stellmacher; P Valent; J Grabbe
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

Review 3.  Contemporary challenges in mastocytosis.

Authors:  H David Pettigrew; Suzanne S Teuber; James S Kong; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  [Mastocytosis and eosinophilic leukemia: diagnostics and classification].

Authors:  K Sotlar; P Valent; H-P Horny
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

5.  Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.

Authors:  H-P Horny; K Sotlar; W R Sperr; P Valent
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.